Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men

Clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa antagonists effectively prevent acute thrombotic events. Orally active GP IIb/IIIa antagonists are essential to evaluate the clinical benefit of long-term treatment. We therefore investigated platelet inhibition by the GP IIb...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 1997-08, Vol.96 (4), p.1130-1138
Hauptverfasser:	MÜLLER, T. H, WEISENBERGER, H, BRICKL, R, NARJES, H, HIMMELSBACH, F, KRAUSE, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Biological and medical sciences Biphenyl Compounds - blood Biphenyl Compounds - pharmacology Blood. Blood coagulation. Reticuloendothelial system Double-Blind Method Humans Infusions, Intravenous Male Medical sciences Pharmacology. Drug treatments Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - blood Platelet Aggregation Inhibitors - pharmacology Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Prodrugs - metabolism Prodrugs - pharmacology Pyrrolidines - blood Pyrrolidines - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!